| Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
|
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial |
|
eJHaem |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
|
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
| Germline mutations in MDS/AML predisposition disorders |
|
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials |
|
Current Medical Research and Opinion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
|
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
